The positive correlation between the concentration of RGMa variant C in the spinal fluid of patients with ALS and their clinical symptoms and the prolonged survival of ALS mice treated with the anti-RGMa antibody suggest that the anti-RGMa antibody inhibits the above-mentioned neuropathogenic effects. This evidence concerns the gene RGMA and amyotrophic lateral sclerosis.